US Stock MarketDetailed Quotes
PALI Palisade Bio
- 2.4400
- 0.00000.00%
Close Nov 22 16:00 ET
- 2.5100
- +0.0700+2.87%
Post 20:01 ET
3.24MMarket Cap-184P/E (TTM)
2.6200High2.3800Low52.85KVolume2.4400Open2.4400Pre Close130.57KTurnover4.04%Turnover RatioLossP/E (Static)1.33MShares22.350052wk High0.49P/B3.19MFloat Cap2.180052wk Low--Dividend TTM1.31MShs Float594000.0000Historical High--Div YieldTTM9.84%Amplitude2.1800Historical Low2.4700Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Palisade Bio Stock Forum
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)
Data to be presented at the 8th Annual Antifibrotic Drug Development (AFDD) Summit
PALI-2108 may offer a solution for fibrostenotic Crohn's disease by enhancing efficacy, safety, and therapeutic potential compared to traditional treatments
Carlsbad, CA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, a clinical-stag...
Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108
Positive
Initiated Phase 1 clinical trial with patient enrollment and dosing for PALI-2108
Received European patent notice for PALI-2108 and PALI-1908
Completed first GMP batch of PALI-2108 drug substance
Successfully demonstrated ex vivo bioactivation in clinical studies
Negative
None.
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis
Palisade Bio (NASDAQ: PALI) has presented positive data from two ex vivo translational studies of PALI-2108, their colon-specific PDE4 inhibitor prodrug for ulcerative colitis treatment. The studies demonstrated successful bioactivation in stool samples and significant TNFα inhibition in whole blood. PALI-2108achieved a 90.1% conversion rat...
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
Palisade Bio (Nasdaq: PALI) has made significant progress towards launching its Phase 1 human clinical study for PALI-2108, a locally activated PDE4 inhibitor prodrug for treating ulcerative colitis (UC). The company has:
1. Completed nonclinical safety and toxicity studies
2. Finalized Phase 1 clinical trial desi...
Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification
Palisade Bio (Nasdaq: PALI) has reported promising data on PDE4B expression as a potential marker for patient stratification in Ulcerative Colitis (UC)treatment.
The company's analysis, conducted in collaboration with Strand Life Sciences, revealed that 70% of adult colitis patients and 90% of pediatric colitis patients show P...
Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, has recently made a advancement in its drug development progr...
No comment yet